Morphine reduced perceived anger from neutral and implicit emotional expressions

Psychoneuroendocrinology
May 2018
https://pubmed.ncbi.nlm.nih.gov/29550675/

Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers

Eur J Pharm Sci
15 September 2018
https://pubmed.ncbi.nlm.nih.gov/29940217/

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care

Cochrane Database Syst Rev
05 June 2018
https://www.ncbi.nlm.nih.gov/pubmed/29869799

Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone

Discov Med
November 2018
https://pubmed.ncbi.nlm.nih.gov/30695679/

Opioid antagonists as potential therapeutics for ischemic stroke

Prog Neurobiol
November 2009
https://pubmed.ncbi.nlm.nih.gov/31398359/#

Early outcomes following low dose naltrexone enhancement of opioid detoxification

Am J Addict
April 2009
https://pubmed.ncbi.nlm.nih.gov/19283561/

Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two clinical trials

Curr Med Res Opinl
17 September 2019
https://pubmed.ncbi.nlm.nih.gov/31456431/

Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy

Int Immunopharmacol
09 August 2019
https://pubmed.ncbi.nlm.nih.gov/31404891/

The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal

Am J Drug Alcohol Abuse
May 2012
https://pubmed.ncbi.nlm.nih.gov/22233189/